Evidence map›Paper›PMID 10511612›Full record

ReviewThe New England journal of medicine1999

Nephropathy in patients with type 2 diabetes mellitus.

E Ritz, S R Orth

Registry-linked trialAbstract readReview
PubMed Publisher
In one paragraph

Review in The New England journal of medicine, 1999. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05037695 (SGLT-2 Inhibitors in Prevention of Post-procedural Renal and Cardiovascular Complications aFter PCI Among Patients With Diabetes Mellitus and Coronary Artery Disease), which is not on this map. Cited by 204 papers, 15 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
204citing papers in PubMed, 15 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05037695 phase4unknown statusstarted 2021, after this paper: background citation

SGLT-2 Inhibitors in Prevention of Post-procedural Renal and Cardiovascular Complications aFter PCI Among Patients With Diabetes Mellitus and Coronary Artery Disease: a Prospective, Randomized, Pilot Study (SAFE-PCI)

Ran2021Enrolled40Registered outcomes17Posted comparisons0ConditionsAcute Kidney Injury, Coronary Artery Disease, Diabetes Mellitus, Type 2Armsempagliflozin 25 mg
Open the trial in the graph
3 · Its place in the literature

Who cites it

204 citing papers in PubMed, 15 syntheses or guidelines pooled it.

  1. Pooled it
  2. Guideline
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Glucose targets for preventing diabetic kidney disease and its progression.The Cochrane database of systematic reviews · 2017
    Pooled it
  7. Pooled it
  8. Vitamin B and its derivatives for diabetic kidney disease.The Cochrane database of systematic reviews · 2015
    Pooled it
  9. Pooled it
  10. Pooled it
  11. Antihypertensive agents for preventing diabetic kidney disease.The Cochrane database of systematic reviews · 2012
    Pooled it
  12. Pentoxifylline for diabetic kidney disease.The Cochrane database of systematic reviews · 2012
    Pooled it
  13. Heparin and related substances for preventing diabetic kidney disease.The Cochrane database of systematic reviews · 2010
    Pooled it
  14. Pooled it
  15. Pooled it
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Gongronema latifolium delays gastric emptying of semi-solid meals in diabetic dogs.African journal of traditional, complementary, and alternative medicines : AJTCAM · 2013
    Trial

144 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

E RitzDepartment of Internal Medicine, Ruperto Carola University, Heidelberg, Germany.
S R Orth

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Diabetic NephropathiesAngiotensin-Converting Enzyme InhibitorsDiabetes Mellitus, Type 2HumansKidney Failure, ChronicRenal InsufficiencyRisk FactorsAngiotensin-Converting Enzyme Inhibitors

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.